Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101608


Historical Background

The family of adhesion G protein coupled receptors (aGPCRs) is the second largest class of GPCRs with increasingly recognized functions in development and disease. Structurally, aGPCRs are characterized by the presence of an extremely long N-terminal region that contains a GPCR autoproteolysis-inducing (GAIN) domain and seven transmembrane spanning regions. Most aGPCRs undergo GAIN domain-mediated autoproteolytic processing to generate an N- and a C-terminal fragment. GPR56/ADGRG1, a member of the adhesion GPCR family, was first cloned in 1999 by two independent groups, one searching for further members of the secretin family of GPCRs and the other screening for differentially expressed genes in a human melanoma metastasis model (Liu et al. 1999; Zendman et al. 1999). However, the function of GPR56 was not known until the discovery of its loss of function mutations linked to an autosomal recessive human brain malformation in 2004. Since then, GPR56 has been found to play several important roles in development and disease, most importantly in the central nervous system (CNS) and the hematopoietic system.

Structure and Signaling of GPR56

GPR56, like other members of the aGPCR family, undergoes GAIN domain-mediated autoproteolytic process to generate an N- and a C-terminal fragment, NTF and CTF, respectively, which remain non-covalently associated at the cell surface (Jin et al. 2007; Shashidhar et al. 2005; Xu et al. 2006). There are a total of seven N-glycosylation sites in the NTF that are required for protein trafficking and appropriate cell surface expression (Jin et al. 2007) (Fig. 1). Human and rodent GPR56 is comprised of 14 exons with the first exon being noncoding regulatory sequence. There are four isoforms of GPR56 that result from alternative splicing in the second and tenth exons (Kim et al. 2010). The first noncoding exon regulates regional and temporal expression of GPR56, and a 15-nucleotide deletion leads to regional cortical malformation (Bae et al. 2014).
GPR56/ADGRG1, Fig. 1

Structure of GPR56. GPR56 is characterized by its long N-terminal domain, autoproteolysis site (called the GPS), 7-transmembrane domain, and C-terminal domain. GPR56 also has several sites of glycosylation along its N-terminal. Binding domains, also found in the N-terminal fragment, for collagen III (27–160), TG2 (108–175), and heparin (26–35, 190–200) are also marked

Truncating GPR56 by removing the NTF up to the GPS results in constitutive receptor activation, indicating that the CTF is constitutively activated (Paavola et al. 2011). It has been theorized that this region comprises a cryptic element required for 7TM domain activation when exposed upon ligand binding. In support of this hypothesis, in vitro studies showed that the binding of GPR56 and its ligand collagen III activates RhoA by removing NTF from its CTF (Luo et al. 2014) (Fig. 2). Further investigation found that active dissociation of the NTF leads to a constitutive activation of GPR56 by uncovering an encrypted tethered-peptide agonist found on the N-terminal end of the CTF, the β-strand-13/stalk region, supporting a tethered agonist signaling mechanism (Stoveken et al. 2015).
GPR56/ADGRG1, Fig. 2

GPR56 Signaling. Collagen III binds the NTF of GPR56, leading to the uncovering of the cryptic tethered agonist which triggers the downstream activation of RhoA. This pathway has been found to be integral to the inhibition of neuronal migration

The first observation that GPR56 signals through RhoA pathway came from an in vitro study using an antibody against the extracellular domain of GPR56 (Iguchi et al. 2008). This finding was subsequently confirmed in a ligand-specific manner. The binding of collagen III to GPR56 activates RhoA, which can be attenuated by dominant negative Gα13, supporting the notion that GPR56 couples to Gα12/13 upon ligand binding. Mice lacking either GPR56 or collagen III display a malformed cerebral cortex, characterized by overmigration of neurons beyond the pial basement membrane (Luo et al. 2011). A very similar phenotype was found in mice lacking Gα12/13 (Moers et al. 2008), further supporting a model in which Gα12/13 is downstream of GPR56 signaling. The definitive evidence for GPR56 coupling to Gα13 came from acellular assays. Human GPR56 was expressed in insect cells, and prepared receptor membranes were reconstituted with purified G protein heterotrimers of defined composition before measurement of receptor-stimulated G protein activation. GPR56 robustly activated Gα13, only modestly coupled to Gi, and did not activated Gq or Gs (Stoveken et al. 2015). This signaling mechanism is not limited to cerebral cortical development. Recent work in mice and zebrafish demonstrated that GPR56 regulate oligodendrocyte proliferation by coupling Gα12/13 and activating RhoA (Ackerman et al. 2015; Giera et al. 2015).

The Ligands and Binding Partners of GPR56

Through work spurred by the discovery of GPR56 as an important mediator in cortical development, collagen III, a protein expressed by meningeal fibroblasts and endothelium of blood vessels in the developing brain, was identified as the primary CNS ligand of GPR56 (Luo et al. 2011). The GPR56-collagen III interaction activates the RhoA pathway by coupling to Gα12/13 and inhibits neuronal migration. Deleting mouse Col3a1 results in a cobblestone-like malformation similar to that seen in Gpr56 knockout mice, further validating collagen III as the primary CNS ligand for GPR56 (Luo et al. 2011). The binding of collagen III removes GPR56 NTF and thus exposes the tethered agonist and activates the receptor (Luo et al. 2014) (Fig. 2).

In the context of melanoma, GPR56 also binds specifically to tissue transglutaminase (TG2), a major cross-linking enzyme in the extracellular matrix that regulates cell adhesion (Xu et al. 2006). TG2 binds the NTF of GPR56 with its two C-terminal β-barrels. This interaction does not appear to induce canonical downstream signaling but instead leads to extracellular matrix remodeling. Recent experiments with a TG2 knockout model demonstrate that GPR56 antagonizes TG2’s inherent cross-linking activity (which promotes melanoma growth) and fibronectin deposition through receptor-mediated internalization and degradation (Yang et al. 2014a).

In an in vitro culture system, the NTF of GPR56 was found to bind heparin, where heparin binding reduces GPR56 receptor shedding without affecting membrane distribution of either the NTF or CTF (Fig. 1) (Chiang et al. 2016). Noting that both known ligands of GPR56, collagen III and TG2, are heparin-binding proteins, it is possible that heparin may influence how GPR56 interacts with its other protein ligands.

Recently, dihydromunduletone (DHM), a rotenoid derivative, was found to be a selective antagonist specifically for adhesion GPCRs GPR56 and GPR114. Its mechanism of action targets GPR56’s CTF directly, acting as a neutral antagonist and competing with the tethered-peptide agonist for its orthosteric binding site, although allosteric modulation is also a possibility. DHM inhibits peptide agonist-stimulated activity, but not basal receptor activity, and its discovery opens the doors to the recognition of further small-molecule modulators of aGPCRs (Stoveken et al. 2016).

GPR56 has also been shown to interact with membrane proteins. In 2004, biochemical approaches first suggested an interaction between GPR56 and Gαq/11, with CD 9 and CD81 acting as scaffolding proteins for signal transduction, although the downstream signaling targets remain unknown (Little et al. 2004). A synergistic function between integrin α3β1 and GPR56 has been demonstrated, in which more severe neuronal overmigration through breached pial basement membranes was observed in a double knockout model than in Gpr56 single knockout (Jeong et al. 2013).

Role in Central Nervous System

GPR56’s first association with human disease was described in 2004 when several mutations in GPR56 were found to cause bilateral frontoparietal polymicrogyria (BFPP), an autosomal recessive disorder characterized by multiple small gyri and abnormal cortical lamination, primarily in the frontoparietal regions of the brain. Clinically, most reported BFPP cases present with a seizure disorder (Piao et al. 2004). There is a distinct association of BFPP cases with Lennox-Gastaut syndrome, a childhood-onset epilepsy that is characterized by frequent seizures of varied types (Parrini et al. 2009). BFPP patients often present with a variety of other neurological symptoms, including severe intellectual disability, global developmental delay, cerebellar ataxia, and a disconjugate gaze. Radiographically, BFPP brains have a number of distinctive radiographic features, including bilateral symmetric polymicrogyria that is most prominent in the frontoparietal regions, with a decreasing anterior-posterior gradient of severity, thinned white matter with areas of T2 prolongation, enlarged ventricles, and a mildly hypoplastic pons and cerebellar vermis (Fig. 3) (Piao et al. 2004). Histopathology of BFPP first came from studies of Gpr56 knockout mice, which displayed cobblestone-like cortical malformation characterized by neuronal overmigration through breaches in the pial basement membrane (Li et al. 2008). This finding was subsequently confirmed in postmortem human BFPP brains (Bahi-Buisson et al. 2010). GPR56 is expressed in radial glial cells and migrating neurons, as well as certain subtypes of preplate neurons, such as Cajal-Retzius cells, which help to establish the framework for further development of the cerebral cortex (Jeong et al. 2012).
GPR56/ADGRG1, Fig. 3

GPR56 Mutations in the nervous system. Patient with disease-causing GPR56 mutations displays a phenotype known as bilateral frontoparietal polymicrogyria. This is characterized by an abnormal folding pattern of the brain surface, created by aberrant neuronal migration, as well as reduced white matter volume (arrows), indicating defects in myelination of the central nervous system

GPR56 also plays an integral role in the myelination of the CNS. Magnetic resonance imaging of BFPP brains displays reduced white matter volume and T2-weighted signal changes, suggestive of defective myelination (Bahi-Buisson et al. 2010; Piao et al. 2005; Piao et al. 2004). The expression of Gpr56 is restricted to oligodendrocyte (OL) precursor cells (OPC) and immature OLs and then downregulated before terminal differentiation (Giera et al. 2015; Zhang et al. 2014). Work from zebrafish and mouse models demonstrates that GPR56 is required for OPC proliferation by activating RhoA pathway (Ackerman et al. 2015; Giera et al. 2015).

Role in Oncologic Disorders

GPR56 was found to be significantly downregulated in high metastatic melanoma cells (Xu et al. 2006; Zendman et al. 1999). Its relation with a variety of oncologic processes has been progressively explored since that initial discovery. Its function as a modulator of cell adhesion and its relationship with the extracellular matrix play an important role in tumor growth and spread. In searches for tumor prognostic factors, GPR56 was found to be differentially expressed or translated in a number of cancers, including overexpression in glioblastomas/astrocytomas (Shashidhar et al. 2005), overexpression in esophageal squamous cell carcinomas, decreased expression in pancreatic cancer, overexpression in childhood T-cell acute lymphoblastic leukemia, overexpression in hepatocellular carcinoma , and overexpression in colorectal cancers, especially in proximal adenocarcinomas. It has also recently been shown that GPR56 is an unfavorable prognostic factor in osteosarcoma patients (Xu et al. 2010).

In primary acute myeloid leukemia (AML) patients, high level GPR56 expression is significantly associated with poor outcomes and can be used as a marker for subpopulations of AML cells with different stem cell-like properties, especially those with high engraftment capacity (Pabst et al. 2016). GPR56 has furthermore been shown to contribute to the development of AML in a mouse model, accelerating myeloid leukemogenesis in vivo, and overexpression of Gpr56 leads to a differential expression of almost 900 genes. Additionally, blocking GPR56 with a monoclonal antibody led to impairment of engraftment of human AML cells into a mouse model (Daria et al. 2016), which may be secondary to impaired cell adhesion and increased cellular migration of AML cells (Saito et al. 2013). GPR56 is also implicated in apoptosis, with increased rates of apoptosis in those AML cells with GPR56 knocked down (Saito et al. 2013).

Through further exploration of the melanoma model, several important functions of GPR56 have been discovered. The internalization and degradation of TG2 was found to be important in the inhibition of melanoma progression (Yang et al. 2014a). Furthermore, GPR56 was shown to regulate VEGF production through protein kinase C activation, which is activated by the CTF (or GPR56 lacking the TG2 binding segment) and inhibited by full-length GPR56, implying the delicate balance GPR56 plays in melanoma progression (Yang et al. 2011).

Role in Hematopoiesis and Lymphocyte Function

GPR56 is required for the maintenance of hematopoietic stem cells (HSCs) during embryonic and adult hematopoiesis (Saito et al. 2013) and in facilitating the process known as endothelial to hematopoietic cell transition (EHT) for generation of the first HSCs, a function evolutionarily conserved between mouse and zebrafish (Solaimani Kartalaei et al. 2015). In Gpr56 −/− mice, both short-term and long-term HSCs were significantly reduced in the bone marrow. However, evidence indicates that some of these HSCs migrate from the bone marrow to peripheral organs where they retain their differentiation capacity, as opposed to those who remain in the bone marrow, which correlates with findings of enlarged thymuses in knockout mice (Saito et al. 2013). Knockdown of Gpr56 results in loss of the repopulating potential of hematopoietic stem cells as well as impaired cellular adhesion (Saito et al. 2013). Its highest expression patterns are within primitive lineages, and this expression declines sharply as these HSCs undergo differentiation into mature blood types, with the absence of GPR56 not significantly affecting steady-state hematopoiesis (Rao et al. 2015).

GPR56 also exerts its function in lymphoid lineage. Human cytotoxic lymphocytes, including NK cells, express GPR56, which is downregulated upon NK cellular activation (Chang et al. 2016; Peng et al. 2011). This expression in lymphocytes is driven by the recently discovered transcription factor Hobit (Chang et al. 2016). Cytomegalovirus infection induces GPR56 expression, starting at the peak of infection and then steadily increasing for up to 1-year postinfection (Peng et al. 2011). Not required for NK cell development, GPR56 is rather a differentiation marker (Chang et al. 2016). It functions as an inhibitory receptor that inhibits immediate effector functions, including inflammatory cytokine and cytolytic protein production, degranulation, and target cell killing. Association with CD81 (but not any G proteins) appears to be critical to these inhibitory functions of GPR56 (Chang et al. 2016). Consisting with those experimental findings with cell line, NK cells isolated from BFPP patients with confirmed GPR56 mutations present with elevated cytotoxic function (Chang et al. 2016).

Role in Other Developmental Processes

GPR56 has a variety of other roles during development and disease. In gonadal development, GPR56 was found to have increased expression during gonadal sex differentiation in female chicken embryo (Ayers et al. 2015) and is required for testis development/male fertility in the mouse (Chen et al. 2010). GPR56 is expressed in skeletal muscle cells and mediates overload-induced muscle hypertrophy and associated anabolic signaling (White et al. 2014). In cardiomyocytes, GPR56 promotes a hypertrophic response that is regulated by a RNA-binding protein, PCBP2 (Zhang et al. 2015). GPR56 displays a decreased expression profile in patients with idiopathic pulmonary fibrosis (Yang et al. 2014b).


GPR56 is an adhesion G protein coupled receptor with a number of important implications in development and disease. It functions through interactions with multiple ligands/binding partners. Some of these have been identified (TG2 and collagen III), but work remains to be continued to characterize the full range of binding partners for GPR56. It works through a diverse range of downstream signaling pathways, including those utilizing canonical G proteins and those dependent on lateral interactions with other membrane proteins such as integrin and tetraspanin proteins. To date, the most notable functions of GPR56 are in the central nervous system development, oncologic disorders, and hematopoiesis. Studies continue to find the importance of GPR56 throughout other developmental processes, from gonadal differentiation to skeletal muscle hypertrophy and pulmonary fibrosis. As further associations to human disease and development are revealed, GPR56 becomes more compelling as an attractive drug target. As GPR56’s structure and function are more thoroughly investigated, light will be also shed on the general family of adhesion GPCRs, many of which remain orphan receptors with unclear mechanisms of action. Unlocking the mysteries of this family may open a field rich with novel therapeutic targets for human disease.


  1. Ackerman SD, Garcia C, Piao X, Gutmann DH, Monk KR. The adhesion GPCR Gpr56 regulates oligodendrocyte development via interactions with Galpha12/13 and RhoA. Nat Commun. 2015;6:6122.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Ayers KL, Lambeth LS, Davidson NM, Sinclair AH, Oshlack A, Smith CA. Identification of candidate gonadal sex differentiation genes in the chicken embryo using RNA-seq. BMC Genomics. 2015;16:704.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Bae BI, Tietjen I, Atabay KD, Evrony GD, Johnson MB, Asare E, et al. Evolutionarily dynamic alternative splicing of GPR56 regulates regional cerebral cortical patterning. Science. 2014;343(6172):764–8.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Bahi-Buisson N, Poirier K, Boddaert N, Fallet-Bianco C, Specchio N, Bertini E, et al. GPR56-related bilateral frontoparietal polymicrogyria: further evidence for an overlap with the cobblestone complex. Brain. 2010;133(11):3194–209.PubMedCrossRefGoogle Scholar
  5. Chang GW, Hsiao CC, Peng YM, Vieira Braga FA, Kragten NA, Remmerswaal EB, et al. The Adhesion G Protein-Coupled Receptor GPR56/ADGRG1 Is an Inhibitory Receptor on Human NK Cells. Cell Rep. 2016;15(8):1757–70.PubMedCrossRefGoogle Scholar
  6. Chen G, Yang L, Begum S, Xu L. GPR56 is essential for testis development and male fertility in mice. Dev Dyn. 2010;239(12):3358–67.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Chiang NY, Chang GW, Huang YS, Peng YM, Hsiao CC, Kuo ML, et al. Heparin interacts with the adhesion GPCR GPR56, reduces receptor shedding, and promotes cell adhesion and motility. J Cell Sci. 2016;129(11):2156–69.PubMedCrossRefGoogle Scholar
  8. Daria D, Kirsten N, Muranyi A, Mulaw M, Ihme S, Kechter A, et al. GPR56 contributes to the development of acute myeloid leukemia in mice. Leukemia. 2016;30(8):1734–41.PubMedCrossRefGoogle Scholar
  9. Giera S, Deng Y, Luo R, Ackerman SD, Mogha A, Monk KR, et al. The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development. Nat Commun. 2015;6:6121.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H. Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. J Biol Chem. 2008;283(21):14469–78. doi:10.1074/jbc.M708919200.Google Scholar
  11. Jeong SJ, Luo R, Li S, Strokes N, Piao X. Characterization of G protein-coupled receptor 56 protein expression in the mouse developing neocortex. J Comp Neurol. 2012;520(13):2930–40.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Jeong SJ, Luo R, Singer K, Giera S, Kreidberg J, Kiyozumi D, et al. GPR56 functions together with alpha3beta1 integrin in regulating cerebral cortical development. PLoS One. 2013;8(7):e68781.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Jin Z, Tietjen I, Bu L, Liu-Yesucevitz L, Gaur SK, Walsh CA, et al. Disease-associated mutations affect GPR56 protein trafficking and cell surface expression. Hum Mol Genet. 2007;16(16):1972–85.PubMedCrossRefGoogle Scholar
  14. Kim JE, Han JM, Park CR, Shin KJ, Ahn C, Seong JY, et al. Splicing variants of the orphan G-protein-coupled receptor GPR56 regulate the activity of transcription factors associated with tumorigenesis. J Cancer Res Clin Oncol. 2010;136(1):47–53.PubMedCrossRefGoogle Scholar
  15. Li S, Jin Z, Koirala S, Bu L, Xu L, Hynes RO, et al. GPR56 regulates pial basement membrane integrity and cortical lamination. J Neurosci. 2008;28(22):5817–26.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Little KD, Hemler ME, Stipp CS. Dynamic regulation of a GPCR-tetraspanin-G protein complex on intact cells: central role of CD81 in facilitating GPR56-Galpha q/11 association. Mol Biol Cell. 2004;15(5):2375–87.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Liu M, Parker RM, Darby K, Eyre HJ, Copeland NG, Crawford J, et al. GPR56, a novel secretin-like human G-protein-coupled receptor gene. Genomics. 1999;55(3):296–305.PubMedCrossRefGoogle Scholar
  18. Luo R, Jeong SJ, Jin Z, Strokes N, Li S, Piao X. G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination. Proc Natl Acad Sci U S A. 2011;108(31):12925–30.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Luo R, Jeong SJ, Yang A, Wen M, Saslowsky DE, Lencer WI, et al. Mechanism for adhesion G protein-coupled receptor GPR56-mediated RhoA activation induced by collagen III stimulation. PLoS One. 2014;9(6):e100043.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Moers A, Nurnberg A, Goebbels S, Wettschureck N, Offermanns S. Galpha12/Galpha13 deficiency causes localized overmigration of neurons in the developing cerebral and cerebellar cortices. Mol Cell Biol. 2008;28(5):1480–8. doi:10.1128/MCB.00651-07.Google Scholar
  21. Paavola KJ, Stephenson JR, Ritter SL, Alter SP, Hall RA. The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. J Biol Chem. 2011;286(33):28914–21.PubMedCrossRefPubMedCentralGoogle Scholar
  22. Pabst C, Bergeron A, Lavallee VP, Yeh J, Gendron P, Norddahl GL, et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016;127(16):2018–27.PubMedCrossRefGoogle Scholar
  23. Parrini E, Ferrari AR, Dorn T, Walsh CA, Guerrini R. Bilateral frontoparietal polymicrogyria, Lennox-Gastaut syndrome, and GPR56 gene mutations. Epilepsia. 2009;50(6):1344–53.PubMedCrossRefGoogle Scholar
  24. Peng YM, van de Garde MD, Cheng KF, Baars PA, Remmerswaal EB, van Lier RA, et al. Specific expression of GPR56 by human cytotoxic lymphocytes. J Leukoc Biol. 2011;90(4):735–40.PubMedCrossRefGoogle Scholar
  25. Piao X, Hill RS, Bodell A, Chang BS, Basel-Vanagaite L, Straussberg R, et al. G protein-coupled receptor-dependent development of human frontal cortex. Science. 2004;303(5666):2033–6.PubMedCrossRefGoogle Scholar
  26. Piao X, Chang BS, Bodell A, Woods K, Benzeev B, Topcu M, et al. Genotype-phenotype analysis of human frontoparietal polymicrogyria syndromes. Ann Neurol. 2005;58(5):680–7.PubMedCrossRefGoogle Scholar
  27. Rao TN, Marks-Bluth J, Sullivan J, Gupta MK, Chandrakanthan V, Fitch SR, et al. High-level Gpr56 expression is dispensable for the maintenance and function of hematopoietic stem and progenitor cells in mice. Stem Cell Res. 2015;14(3):307–22.PubMedCrossRefPubMedCentralGoogle Scholar
  28. Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, et al. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56. Leukemia. 2013;27(8):1637–49.PubMedCrossRefGoogle Scholar
  29. Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J, et al. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene. 2005;24(10):1673–82.PubMedCrossRefGoogle Scholar
  30. Solaimani Kartalaei P, Yamada-Inagawa T, Vink CS, de Pater E, van der Linden R, Marks-Bluth J, et al. Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation. J Exp Med. 2015;212(1):93–106.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Stoveken HM, Hajduczok AG, Xu L, Tall GG, Adhesion G. Protein-coupled receptors are activated by exposure of a cryptic tethered agonist. Proc Natl Acad Sci U S A. 2015;112(19):6194–9.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Stoveken HM, Bahr LL, Anders MW, Wojtovich AP, Smrcka AV, Tall GG. Dihydromunduletone is a small-molecule selective adhesion G protein-coupled receptor antagonist. Mol Pharmacol. 2016;90(3):214–24.PubMedCrossRefPubMedCentralGoogle Scholar
  33. White JP, Wrann CD, Rao RR, Nair SK, Jedrychowski MP, You JS, et al. G protein-coupled receptor 56 regulates mechanical overload-induced muscle hypertrophy. Proc Natl Acad Sci U S A. 2014;111(44):15756–61.PubMedCrossRefPubMedCentralGoogle Scholar
  34. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2006;103(24):9023–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, et al. GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis. 2010;27(4):241–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56 Regulates VEGF production and angiogenesis during melanoma progression. Cancer Res. 2011;71(16):5558–68.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Yang L, Friedland S, Corson N, Xu L. GPR56 inhibits melanoma growth by internalizing and degrading its ligand TG2. Cancer Res. 2014a;74(4):1022–31.PubMedCrossRefGoogle Scholar
  38. Yang J, Wang Z, Leng D, Dai H, Wang J, Liang J, et al. G protein-coupled receptor 56 regulates matrix production and motility of lung fibroblasts. Exp Biol Med (Maywood). 2014b;239(6):686–96.CrossRefGoogle Scholar
  39. Zendman AJ, Cornelissen IM, Weidle UH, Ruiter DJ, van Muijen GN. TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential. FEBS Lett. 1999;446(2–3):292–8.PubMedCrossRefGoogle Scholar
  40. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929–47.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Zhang Y, Si Y, Ma N, Mei J. The RNA-binding protein PCBP2 inhibits Ang II-induced hypertrophy of cardiomyocytes though promoting GPR56 mRNA degeneration. Biochem Biophys Res Commun. 2015;464(3):679–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Newborn MedicineBoston Children’s Hospital, Harvard Medical SchoolBostonUSA